Template:Ceftriaxone: Difference between revisions
Jump to navigation
Jump to search
Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; ! style="padding: 0 5px; font-size: 100%; background:#F8F8..." |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Ceftriaxone|{{fontcolor|#6C7B8B|Ceftriaxone}}]]''''' | ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Ceftriaxone|{{fontcolor|#6C7B8B|Ceftriaxone}}]]''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left |CEFTRIAXONE<sup>®</sup> FDA Package Insert | ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left |CEFTRIAXONE<sup>®</sup>,ROCEPHIN<sup>®</sup> FDA Package Insert | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftriaxone description|Description]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftriaxone description|Description]] | ||
| Line 23: | Line 23: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftriaxone clinical studies|Clinical Studies]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftriaxone clinical studies|Clinical Studies]] | ||
|- | |||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftriaxone Compatibility and Stability|Compatibility and Stability]] | |||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftriaxone how supplied|How Supplied]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Ceftriaxone how supplied|How Supplied]] | ||